As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
20 Analysts have issued a Scholar Rock Holding Corp. forecast:
20 Analysts have issued a Scholar Rock Holding Corp. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -360 -360 |
58%
58%
|
|
| EBIT (Operating Income) EBIT | -362 -362 |
57%
57%
|
|
| Net Profit | -353 -353 |
56%
56%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | David Hallal |
| Employees | 128 |
| Founded | 2012 |
| Website | scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


